Pagibaximab
Based on 1 Customer Validation
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.81%
- CAS No.: 595566-61-3
- Masse moléculaire:145.42 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
LTA
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 595566-61-3
-
Appearance Liquid
-
Masse moléculaire 145.42 kDa
-
Color Colorless to light yellow
-
SMILES
[Pagibaximab]
-
Synonyms
BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (254 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)